发作特征和结局在患有多形性黄星细胞瘤的患者
Daniel J Zhou1,2, Colin A Ellis1,2, Kevin Xie3,1
1Center for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Neuro-oncology advances
|July 28, 2025
概括
形的桑托阿斯特罗细胞瘤 (PXA) 经常导致. 经过BRAF突变的PXA瘤表现出明显的模式,影响手术后的控制,但长期存活率与无关.
科学领域:
- 神经瘤学神经瘤学
- 发病学 (Epileptology) 是一个专业的学科.
背景情况:
- 形黄细胞瘤 (PXA) 是一种罕见的大脑瘤,经常与有关.
- 关于PXA中的现象,关于瘤生物学和生存结果的数据有限.
研究的目的:
- 在PXA患者中描述现象.
- 探索PXA瘤生物学,和生存之间的关系.
主要方法:
- 35名PXA患者的回顾性观察研究.
- 评估人口统计学,临床特征和状态.
- 对瘤切除后的发作自由度的分析.
主要成果:
- 77%的患者患上了与瘤相关的发作 (TRE),71%最初出现了发作.
- 与BRAF突变的PXA和非额叶局部化相关的TRE.
- 初始切除后的发作自由与较年轻的发病年龄,较小的瘤大小和BRAF突变有关.
结论:
- BRAF突变和BRAF野生型PXAs表现出不同的现型.
- 对瘤生物学和发作的进一步研究可能会指导针对PXA相关的向治疗.
关键词:
大脑瘤是个大脑瘤结果就是结果.pleomorphic xanthoastrocytoma pleomorphic xanthoastrocytoma 是一种多态的植物性细胞瘤,它是一种多态的植物性细胞瘤.发作 发作 发作与瘤相关的发症更多相关视频
相关概念视频
Seizures: Classification
596
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
596
Epilepsy and Seizures: Overview
281
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
281
Aneurysm II: Clinical Manifestations and Diagnostic Studies
24
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
24
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
451
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
451
Antiepileptic Drugs: Potassium Channel Activators
278
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
278


